Vimarsana
Biggest News Aggregation in the World

Page 14 - Arnaud Delepine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arnaud Delepine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arnaud Delepine Today - Breaking & Trending Today

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2 - Vimarsana News

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2 Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2 Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1 THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi's Synthorin technology platform, is being studied in a...

Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ... - Vimarsana News

Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ... SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival                                                                                                                           Â...

Source: apnews.com
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate - Vimarsana News

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels Expected to enroll 415 participants; interim results expected in Q3 2021 In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants PARIS and LEXINGTON, MASS. - March 12, 2021 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRN...

Investegate |Sanofi Announcements | Sanofi: Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members - Vimarsana News

Investegate |Sanofi Announcements | Sanofi: Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members

Sanofi Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Paris, France – March 3, 2021 – At its meeting on March 3, 2021, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2021, the appointment of two new Directors, Chr...

Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members - Vimarsana News

Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members

Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Paris, France - March 3, 2021 - At its meeting on March 3, 2021, Sanofi's Board of Directors